Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin’s pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Travere Therapeutics is headquartered in San Diego, California, the US.

Travere Therapeutics Inc Key Recent Developments

Nov 16,2020: Retrophin announces corporate name change to Travere Therapeutics
Jul 30,2020: Retrophin reports second quarter 2020 financial results
May 11,2020: Retrophin reports first quarter 2020 financial results
Apr 09,2020: Retrophin appoints Suzanne L. Bruhn, Ph.D. to Board of Directors
Mar 10,2020: Ligand’s presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company
Travere Therapeutics Inc - Key Facts
Travere Therapeutics Inc - Key Employees
Travere Therapeutics Inc - Key Employee Biographies
Travere Therapeutics Inc - Major Products and Services
Travere Therapeutics Inc - History
Travere Therapeutics Inc - Company Statement
Travere Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Travere Therapeutics Inc - Business Description
Product Category: Bile Acid Products
Overview
Performance
Product Category: Thiola
Overview
Performance
R&D Overview
Travere Therapeutics Inc - Corporate Strategy
Travere Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Travere Therapeutics Inc - Strengths
Travere Therapeutics Inc - Weaknesses
Travere Therapeutics Inc - Opportunities
Travere Therapeutics Inc - Threats
Travere Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Travere Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 16, 2020: Retrophin announces corporate name change to Travere Therapeutics
Jul 30, 2020: Retrophin reports second quarter 2020 financial results
May 11, 2020: Retrophin reports first quarter 2020 financial results
Apr 09, 2020: Retrophin appoints Suzanne L. Bruhn, Ph.D. to Board of Directors
Mar 10, 2020: Ligand’s presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com
Feb 28, 2020: Retrophin recognizes Rare Disease Day 2020 and the importance of working together toward more equitable access to care
Feb 24, 2020: Retrophin reports fourth quarter and full year 2019 financial results
Jan 13, 2020: Retrophin provides corporate update and 2020 outlook
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


List Of Tables


Travere Therapeutics Inc, Key Facts
Travere Therapeutics Inc, Key Employees
Travere Therapeutics Inc, Key Employee Biographies
Travere Therapeutics Inc, Major Products and Services
Travere Therapeutics Inc, History
Travere Therapeutics Inc, Other Locations
Travere Therapeutics Inc, Subsidiaries
Travere Therapeutics Inc, Key Competitors
Travere Therapeutics Inc, Ratios based on current share price
Travere Therapeutics Inc, Annual Ratios
Travere Therapeutics Inc, Annual Ratios (Cont...1)
Travere Therapeutics Inc, Annual Ratios (Cont...2)
Travere Therapeutics Inc, Interim Ratios
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Travere Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios


List Of Figures


Travere Therapeutics Inc, Performance Chart (2015 - 2019)
Travere Therapeutics Inc, Ratio Charts
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Anika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major

USD 750 View Report

Chinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available